Portage Biotech Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Portage Biotech Inc.
Scrip Asks...What Does 2023 Hold For Biopharma? Part 2: M&A And Partnering
Deal-making between big pharma and biotech looks set to rise with a looming patent cliff increasing the need for the former to replenish its pipelines. Meanwhile, biotechs need partners to help them advance amid the ongoing big freeze on raising cash on public markets.
Scrip Asks...What Does 2023 Hold For Biopharma? Part 1: The Funding Environment
With valuations down and borrowing costs up, many industry insiders are expecting Darwinian scenes in biotech this year. Survival of the fittest is the order of the day: companies with riskier, less commercially defined propositions will struggle, while platform companies with multiple shots on strong goals will increasingly find favor in a more risk-averse environment.
Portage Buys Tarus, Gaining Cancer Assets Targeting Immune Evasion
Acquisition valued at roughly $21m upfront for two clinical and two preclinical adenosine receptor antagonists.
Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
- Drug Delivery
- Drug Discovery Technologies
- Large Molecule
Drug Discovery Technologies
- Other Names / Subsidiaries
- 3Legs Resources plc
- Biohaven Pharmaceutical Holding Company Ltd.
- Bontan Corporation, Inc.
- Intensity Holdings Limited
- Intensity Therapeutics, Inc.
- iOx Therapeutics, Ltd
- Portage Acquisition Inc.
- Portage Pharmaceuticals Limited (PPL)
- JV Co
- Portage Glasgow Limited (PGL)
- Nekonal SARL
- SalvaRx Limited
- Saugatuck Therapeutics Ltd.
- Rift Biotherapeutics
- SalvaRx Group plc
- Tarus Therapeutics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.